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Research article

Glucocorticoids exacerbate obesity and
insulin resistance in neuron-specific
proopiomelanocortin-deficient mice
James L. Smart,1 Virginie Tolle,1 and Malcolm J. Low1,2,3
1Vollum

Institute, 2Department of Behavioral Neuroscience, and 3Center for the Study of Weight Regulation and
Associated Disorders, Oregon Health & Science University, Portland, Oregon, USA.

Null mutations of the proopiomelanocortin gene (Pomc–/–) cause obesity in humans and rodents, but the
contributions of central versus pituitary POMC deficiency are not fully established. To elucidate these roles,
we introduced a POMC transgene (Tg) that selectively restored peripheral melanocortin and corticosterone
secretion in Pomc–/– mice. Rather than improving energy balance, the genetic replacement of pituitary POMC
in Pomc–/–Tg+ mice aggravated their metabolic syndrome with increased caloric intake and feed efficiency,
reduced oxygen consumption, increased subcutaneous, visceral, and hepatic fat, and severe insulin resistance. Pair-feeding of Pomc–/–Tg+ mice to the daily intake of lean controls normalized their rate of weight
gain but did not abolish obesity, indicating that hyperphagia is a major but not sole determinant of the phenotype. Replacement of corticosterone in the drinking water of Pomc–/– mice recapitulated the hyperphagia,
excess weight gain and fat accumulation, and hyperleptinemia characteristic of genetically rescued Pomc–/–Tg+
mice. These data demonstrate that CNS POMC peptides play a critical role in energy homeostasis that is not
substituted by peripheral POMC. Restoration of pituitary POMC expression to create a de facto neuronal
POMC deficiency exacerbated the development of obesity, largely via glucocorticoid modulation of appetite,
metabolism, and energy partitioning.
Introduction
Deciphering the complex regulatory mechanisms for energy balance is a health-care priority because of the rapidly growing prevalence of obesity (1). Energy homeostasis is enabled by peripheral
signals informing the CNS about energy storage levels and metabolic status. Vagal afferents and hormones including leptin, insulin, ghrelin, and glucocorticoids relay this interoceptive information to hypothalamic and brainstem nuclei that in turn regulate
energy consumption, utilization, and storage (2, 3). Peripheral
information processed centrally is used to elicit appropriate feeding, endocrine, and autonomic motor responses.
Neurons in the arcuate nucleus of the hypothalamus that express
the gene encoding proopiomelanocortin (POMC) play a major role
in this physiological network (4–6). Genetic disruption of either
the mouse Pomc or the human POMC gene causes early-onset obesity (7–9), suggesting that endogenous POMC pathways are essential for the regulation of energy homeostasis. POMC is processed
posttranslationally to the endogenous opioid β-endorphin and
the melanocortin peptides ACTH, α-melanocyte-stimulating hormone (αMSH), βMSH, and γMSH. Absence of some or all of these
peptides could potentially contribute to the obesity syndrome. In
the CNS, energy balance is profoundly modulated by the anorexigenic peptide αMSH via melanocortin receptor-4 (MC4-R) activation. Central administration of αMSH (10, 11) or a synthetic
analog, MTII (12, 13), reduces food intake in rodents. Conversely,
mutations of MC4-R, the most abundant melanocortin receptor
Nonstandard abbreviations used: HPA, hypothalamic-pituitary-adrenal; MC4-R,
melanocortin receptor-4; MSH, melanocyte-stimulating hormone; POMC, proopiomelanocortin; RQ, respiratory quotient.
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in the CNS, lead to obesity in humans and mice (14–21). MC4-R is
also a target for agouti-related protein (AGRP), a naturally occurring receptor antagonist released from terminals of neuropeptide
Y/AGRP arcuate nucleus neurons that parallel the distribution of
POMC fibers throughout the limbic system (22). The less abundant MC3-R appears to play a distinct role from activation of
MC4-R in energy homeostasis (23, 24). Furthermore, β-endorphin
has independent modulatory effects on appetite, satiety, and food
reinforcement in the brain’s reward circuitry (25, 26).
Intermediate lobe pituitary melanotrophs are the major source of
circulating αMSH, although the importance of peripheral αMSH
in energy homeostasis is unclear. Anterior lobe corticotrophs
secrete ACTH that stimulates the production of glucocorticoids
from the adrenals. Therefore, a disruption in pituitary POMC function could impact energy balance secondarily via altered levels of
glucocorticoid hormones, which regulate metabolism, fat distribution, and the development of obesity independently of αMSH (3).
Corticosterone is known to play a permissive role in rodents for
positive energy balance. Adrenalectomy normalizes several metabolic abnormalities observed in rodents with monogenic obesity
syndromes, and the effects of adrenalectomy can be reversed by
glucocorticoid replacement (27–32). Furthermore, chronic hypersecretion of cortisol associated with Cushing syndrome is associated
with altered fat distribution and visceral obesity (33).
While the majority of energy homeostasis studies have focused
on CNS POMC, a requirement for pituitary POMC peptides, either
directly through peripheral actions of melanocortins (34) or indirectly
via glucocorticoids, has not been established conclusively. Here, we
compare Pomc–/– mice with a global deficiency of POMC with a compound mutant strain of Pomc–/–Tg+ mice with a neuron-specific deficiency of POMC to differentiate the roles played by central and peripheral POMC peptides in the control of feeding and metabolism.
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Figure 1
Transgenic rescue of pituitary POMC expression. (A) Schematic of WT Pomc+, null Pomc–, and pHalEx2* Tg alleles. A neomycin (Neo) selection cassette replaces exon 3 in the Pomc– allele, and a 23-bp oligonucleotide (asterisk) is inserted in the 5′ untranslated region of exon 2 of the
Tg allele. The arrow above exon 1 represents the transcriptional start site. PCR primer locations for genotyping of the Pomc+ (i and ii), Pomc–
(iii and iv), and Tg (v and vi) alleles are indicated by half-arrows. (B and C) ACTH immunoreactivity in the pituitary anterior lobe (AL), intermediate lobe (IL), and medial basal hypothalamus (MBH) from mice of the indicated genotypes. 3V, third ventricle. Scale bars: 300 µm (pituitary)
and 100 µm (MBH). (D and E) Quantitation of αMSH content in the pituitary gland and MBH from male mice of the indicated genotypes (n = 4).
*P < 0.01, **P < 0.001, and ***P < 0.0001 compared with Pomc+/+Tg+. (F) Basal diurnal corticosterone levels in 10- to 15-week-old male and
female Pomc+/+Tg+ and Pomc–/–Tg+ mice.

Results
Transgenic rescue of pituitary POMC in Pomc–/– mice. Transgenic mice
were generated with a modified genomic construct predicted to
express POMC in pituitary cells but not neurons (35, 36). The
Pomc WT (Pomc+), KO (Pomc–), and pHalEx2* transgenic (Tg) alleles
are depicted schematically in Figure 1A. Hemizygous Tg+ transgenic mice were intercrossed to Pomc+/– mice to generate Pomc+/–Tg+
breeders. Pomc+/–Tg+ females were subsequently bred with either
Pomc+/+ or Pomc–/– males to generate Pomc+/+, Pomc+/–, and Pomc–/–
mice with or without the transgene (Tg+ or +/+, respectively).
Immunohistochemical detection of ACTH (Figure 1, B and C)
or β-endorphin (data not shown) confirmed tissue-specific
expression of the pHalEx2* transgene with restoration of peptide
immunoreactivity in the pituitary anterior and intermediate lobes
(Figure 1B) but not the hypothalamus (Figure 1C) of Pomc–/–Tg+
mice. Fully processed αMSH (ACTH 1-13-amide) was quantified
by RIA of tissue extracts (Figure 1, D and E). Hypothalamic αMSH
was reduced by 50% in Pomc+/– mice and was undetectable in both
Pomc–/– and Pomc–/–Tg+ mice. Pituitary αMSH was undetectable
only in Pomc–/– mice but was similarly high (100–200 pmol per
pituitary) in the other genotypes, including the Pomc–/–Tg+ mice.
Furthermore, plasma levels of αMSH in Pomc–/–Tg+ mice were
restored to the normal range of Pomc+/+Tg+ mice (54 ± 42 versus
48 ± 35 fmol/ml, respectively).
496
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Plasma corticosterone levels were measured in 10- to 15-weekold mice at 3-hour intervals from 0800 to 2000 hours (Figure 1F)
to assess the effects of genetically restored pituitary expression
of ACTH on the hypothalamic-pituitary-adrenal (HPA) axis.
Pomc+/+Tg+ mice exhibited the WT diurnal rhythm of corticosterone secretion with a nadir early in the light phase and increasing levels before the onset of darkness. Female Pomc+/+Tg+ mice
had higher peak corticosterone values than males, reflecting the
normal sexual dimorphism of the HPA axis. Pomc–/– mice of both
sexes had undetectable corticosterone at all time points. Female
Pomc–/–Tg+ mice retained a diurnal pattern of corticosterone secretion with normal basal and only modestly increased peak values.
In contrast, male Pomc–/–Tg+ mice exhibited an altered pattern of
corticosterone secretion with exaggerated nadir and peak levels.
pHalEx2* transgene expression did not alter corticosterone levels
in the Pomc+/– background (data not shown).
Long-term effects of pituitary POMC rescue in Pomc –/– mice on
growth, adipose mass, and glucose homeostasis. The complete absence
of POMC in Pomc –/– mice resulted in significantly increased
body weight in both sexes compared with that of Pomc+/+ mice,
while haploinsufficiency in Pomc +/– mice produced a more
subtle intermediate phenotype evident primarily in males (Figure 2A). Expression of the pHalEx2* transgene had no effect
on weight gain in either Pomc+/+Tg+ or Pomc+/–Tg+ mice. In con-
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Figure 2
The effects of rescued pituitary POMC expression
on body weight and length in the Pomc–/– background. (A) Body weight curves for male and female
Pomc+/+, Pomc+/–, and Pomc–/– mice with and without the pHalEx2* transgene (n = 9–44). Repeatedmeasures ANOVAs from 1 to 26 weeks old showed
interactions between week and genotype for both
sexes. Males: P < 0.0001, Pomc–/–, Pomc–/–Tg+, and
Pomc+/–Tg+ compared with Pomc+/+ or Pomc+/+Tg+;
P < 0.001, Pomc +/– compared with Pomc +/+ or
Pomc+/+Tg+. Females: P < 0.0001, Pomc–/– and
Pomc–/–Tg+ compared with Pomc+/+ or Pomc+/+Tg+.
(B) Body lengths of males at age 44 ± 1.3 weeks
and females at age 59 ± 2 weeks differed by genotype (F5,44 = 5.9, P < 0.0005, and F 5,37 = 13.4,
P < 0.0001, respectively). *P < 0.01, **P < 0.001,
and ***P < 0.0001 compared with Pomc+/+.

trast, restoration of peripheral POMC expression in Pomc–/–Tg+
mice markedly augmented weight gain compared with all other
genotypes. As early as age 4 weeks, Pomc–/–Tg+ mice weighed significantly more than Pomc–/– mice. By age 26 weeks, male and
female Pomc–/–Tg+ mice had gained 30% and 40% more weight,
respectively, than their Pomc–/– siblings. Increased body weight
was partially due to increased linear growth in Pomc +/– and
Pomc–/– mice of both sexes (Figure 2B). However, the pHalEx2*
transgene did not further alter body length in these animals,
indicating that it was the loss of CNS and not pituitary POMC
peptides that directly or indirectly accentuated linear growth
in Pomc mutants.
Altered lipid accumulation in both intra-abdominal and subcutaneous fat depots was responsible for most of the differences in body weight among genotypes (Figure 3). Renal, visceral,
gonadal, and subcutaneous inguinal fat pads were all significantly heavier in Pomc–/– compared with Pomc+/+ or Pomc+/+Tg+ mice,
with the largest increase occurring in gonadal fat. Pomc–/–Tg+
mice had further increases in the mass of renal, visceral, and
inguinal white fat pads, with a disproportionately greater
change in inguinal fat (data shown for females only). Interestingly, the gonadal fat pads of male Pomc–/–Tg+ mice were similar
in weight to those of Pomc+/+ siblings and smaller than those of
Pomc–/– siblings for either sex despite large increases in all other
adipose depots. Liver mass was also substantially increased with

prominent steatosis in Pomc–/–Tg+ mice. Consistent with their
elevated body weights, heterozygous Pomc +/– and Pomc +/–Tg +
males displayed modest increases in fat pad and liver mass.
Fasting blood glucose and insulin levels were obtained at age 6–8
months (Table 1). Male Pomc–/– and Pomc–/–Tg+ mice exhibited significantly elevated fasting glucose levels. However, only Pomc–/–Tg+
mice of both sexes had significantly elevated fasting insulin levels
compared with all other genotypes. The homeostasis assessment
(HOMA) index was calculated to estimate the magnitude of insulin resistance (Table 1), and a 2-factor ANOVA demonstrated highly significant main effects of genotype (F5,110 = 24.4, P < 0.0001)
and sex (F1,110 = 26.9, P < 0.0001, male > female) but no interaction
between the 2 variables. In parallel to their insulin levels, Pomc–/–

Figure 3
Weights of adipose tissue and liver from male and female Pomc+/+,
Pomc+/–, and Pomc–/– mice with and without pHalEx2* transgene
expression. Adipose depots are the combined renal/visceral, gonadal, and subcutaneous inguinal white fat pads. The box and whisker
plots show the 10th, 25th, 50th (median), 75th, and 90th percentiles
and individual outlying data points (open circles). Males, age 41 ± 1
weeks (n = 3–10). Females, age 55 ± 1.7 weeks (n = 4–6). *P < 0.05,
**P < 0.01, and ***P < 0.0001 compared with Pomc+/+.
The Journal of Clinical Investigation
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Table 1
Glucose homeostasis in WT and mutant Pomc mice

Genotype

Glucose (mg/dl)

Male
Insulin (ng/ml)

HOMA index

Glucose (mg/dl)

Female
Insulin (ng/ml)

HOMA index

Pomc+/+
Pomc+/+Tg+
Pomc+/–
Pomc+/–Tg+
Pomc–/–
Pomc–/–Tg+

89 ± 7
94 ± 8
108 ± 7
102 ± 9
124 ± 8A
125 ± 13A

0.73 ± 0.20
0.99 ± 0.30
0.86 ± 0.14
1.38 ± 0.20
1.15 ± 0.17
2.91 ± 0.54B

4.7 ± 1.8
6.5 ± 2.4
6.1 ± 1.0
9.6 ± 1.9
8.9 ± 1.1
26.5 ± 6.5B

83 ± 5
78 ± 6
85 ± 6
88 ± 7
85 ± 13
89 ± 6

0.46 ± 0.08
0.60 ± 0.20
0.36 ± 0.03
0.32 ± 0.06
0.78 ± 0.33
2.52 ± 0.33B

2.7 ± 0.6
3.6 ± 1.6
1.9 ± 0.2
1.8 ± 0.3
4.6 ± 2.2
14.8 ± 2.4B

Fasting glucose and insulin levels were from 6- to 8-month-old mice (n = 5–23). The homeostasis assessment (HOMA) index of insulin resistance was calculated using the formula [blood glucose (mmol/l)][plasma insulin (mU/l)]/22.5. AP < 0.01 versus Pomc+/+ and Pomc+/+Tg+; BP < 0.0001 versus all other genotypes.

Tg+ mice had increased HOMA values (P < 0.0001 compared with
each other genotype), while the index in glucocorticoid-deficient
Pomc–/– mice was only marginally different from that in Pomc+/+ or
Pomc+/– mice (P < 0.05 for both comparisons).
Development and maintenance of obesity in young and adult Pomc–/– and
Pomc–/–Tg+ mice were due to distinct combinations of altered food intake and
metabolic rate. Our initial characterization studies involved all 6 possible genotypes of compound mutant mice and revealed a relatively
mild phenotype in male Pomc+/– mice and no effect of pHalEx2* Tg
expression on energy balance in the Pomc+/+ or Pomc+/– genetic background. Therefore, we limited our follow-up studies with additional cohorts of mice to the 3 most informative genotypes that could
also be generated by a more efficient breeding strategy: Pomc–/– and
Pomc–/–Tg+ experimental groups and a Pomc+/+Tg+ control group.
At age 6 weeks, Pomc–/– and Pomc–/–Tg+ mice were hyperphagic and
consumed 25% and 60% more food, respectively, over 24 hours compared with Pomc+/+Tg+ controls (Figure 4A). In contrast, by age 26
weeks, there was no longer a measurable difference in 24-hour food
intake between Pomc–/– and Pomc+/+Tg+ mice, although Pomc–/–Tg+
mice remained overtly hyperphagic at essentially the same level

exhibited at age 6 weeks (Figure 4B). After normalization of food
intake to estimated metabolic mass with the scaling formula
described by Pace et al. (37), Pomc–/– and Pomc–/–Tg+ mice remained
hyperphagic compared with their Pomc+/+Tg+ siblings at age 6 weeks
(Figure 4C). However, by age 9 weeks, all genotypes consumed
the same quantity of food relative to their estimated metabolic
mass. Despite continued increases in body weight over time, the
absolute daily food intake for each genotype remained essentially
constant between ages 9 and 26 weeks. Consequently, normalized
food intake continued to decrease and was actually significantly
lower in all POMC-deficient mice compared with their Pomc+/+Tg+
control siblings at age 26 weeks (Figure 4C). This trend was more
pronounced in Pomc–/– than in Pomc–/–Tg+ mice.
To explain the maintenance of obesity in the mutant mice in
the context of their measured drop in either absolute or normalized caloric intake, we assessed basal metabolic rates by indirect
calorimetry. VO2 was measured during the animals’ least active
phase of the diurnal light-dark cycle and expressed relatively to
estimated metabolic mass using the scaling formula. At age 10
weeks, when body weights were relatively more similar among

Figure 4
Food intake in Pomc+/+Tg+, Pomc–/–, and Pomc–/–Tg+ mice provided ad libitum access to chow. (A and B) There were genotype differences in 24-hour
food intake in 6-week-old males (F2,17 = 25.8, P < 0.0001) and females (F2,15 = 5.418, P < 0.05) (A) and in 26-week-old males (F2,19 = 20.2,
P < 0.0001) and females (F2,21 = 30.5, P < 0.0001) (B). (C) Genotype differences were also observed in 24-hour food intake corrected for metabolic mass ([food intake (g)]/[body weight (g)]0.75 × 100) at ages 6 weeks (F2,32 = 4.1, P < 0.05) and 26 weeks (F2,45 = 6.6, P < 0.005) but not at
age 9 weeks (F2,21 = 0.2, P = 0.82) (males and females combined). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with Pomc+/+Tg+.
498
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sible age (5–6 weeks old) before obesity fully developed and
continued until the velocity of weight gain started to decline
(15–20 weeks old). Food restriction of Pomc–/–Tg+ mice to
the average daily intake of Pomc+/+Tg+ controls immediately
decreased the velocity of weight gain from approximately
2.5 to 0.5 g/wk, identical to that in Pomc+/+Tg+ mice provided
ad libitum chow (Figure 6A). However, the absolute weight
of pair-fed Pomc–/–Tg+ mice remained significantly elevated
compared with that of Pomc+/+Tg+ mice at all time points
(P < 0.0001) and was nearly identical to that of ad libitum–
fed Pomc–/– mice. At age 10 weeks, after 4 weeks of pair-feeding, Pomc–/–Tg+ males but not females exhibited an increase
in VO2 to nearly normal levels (Figure 5A).
Consistent with the failure of 10 weeks of caloric restriction to normalize body weight, white fat mass of the pair-fed
Pomc–/–Tg+ mice was intermediate to that of ad libitum–fed
Pomc–/–Tg+ and Pomc+/+Tg+ mice but similar to that of ad libitum–fed Pomc–/– mice for both sexes (Figure 6B). These differences in fat pad weight among genotypes and in response
to pair-feeding were mirrored by the concentrations of
plasma leptin. Fasting leptin levels were elevated 10-fold in
Pomc–/–Tg+ mice compared with both Pomc–/– and Pomc+/+Tg+
mice as early as age 6 weeks (data not shown). Hyperleptinemia became more pronounced at age 9 weeks (Figure 6C),
and by age 15–20 weeks, leptin levels were 25-fold higher in
ad libitum–fed Pomc–/–Tg+ mice compared with Pomc+/+Tg+
Figure 5
mice (Figure 6D). In contrast, average leptin levels in ad libiBasal metabolic rate and RQ. (A and B) Basal metabolic rate measured by tum–fed Pomc–/– mice were only 4-fold higher than those in
VO2 consumption corrected for metabolic mass (ml/kg0.75/h) in 10-week-old Pomc+/+Tg+ controls at age 15–20 weeks (Figure 6D) and also
(A) and 30-week-old (B) mice (n = 5–9). Basal metabolic rate differed by
at age 26–30 weeks (data not shown). Pair-feeding of Pomc–/–
genotype in males (F3,18 = 3.2, P < 0.05) but not females (F3,20 = 1.7, P = 0.19)
Tg+ mice resulted in substantial reductions in plasma leptin
at age 10 weeks (A) and in both males (F2,18 = 6.1, P < 0.01) and females
(F2,18 = 6.8, P < 0.01) at age 30 weeks (B). PF, pair-fed. **P < 0.01 compared at ages 9 and 15–20 weeks compared with ad libitum feeding,
with Pomc+/+Tg+. (C) RQ was higher in both male and female Pomc–/–Tg+ but parallel to the relative changes in fat pad weight, leptin
compared with Pomc–/– and Pomc+/+Tg+ mice at age 30 weeks. Repeated- levels of pair-fed Pomc–/–Tg+ mice remained higher than those
measures ANOVAs showed a main effect of genotype for males (F2,198 = 3.4, of Pomc–/– mice of comparable total body weight.
P = 0.05) and females (F2,198 = 24.6, P < 0.0001).
Corticosterone replacement augmented weight gain and obesity in Pomc–/– mice. To determine whether glucocorticoids,
independently of pituitary POMC, accounted for the
genotypes compared with older ages, but the velocity of weight increased obesity phenotype in the genetically rescued mice, we
gain was at its maximal slope, VO2 was trending downward by performed 2 pharmacological replacement experiments, treating
5–6% in Pomc –/– mice versus Pomc +/+Tg+ control mice of both Pomc–/– mice of both sexes with a fixed concentration of 25 µg
sexes (Figure 5A). However, at age 30 weeks, when the obesity corticosterone per milliliter drinking water.
phenotype was fully developed and the velocity of weight gain
In the first experiment, groups of male and female Pomc–/–
much more shallow, VO2 was significantly decreased by 24% in mice were chronically treated with corticosterone in their drinkPomc–/– females compared with Pomc+/+Tg+ siblings, indicating ing water starting at age 5–6 weeks or provided with ordinary
that the metabolic defect worsened with age and/or degree of drinking water. Diurnal corticosterone levels in the treated
obesity (Figure 5B). VO2 was more consistently altered in Pomc–/– Pomc–/– mice at ages 10–15 weeks were within the physiologiTg+ mice at both ages, with 22% and 15% reductions in males and cal range: 0800 hours male, 41 ± 16 ng/ml; 0800 hours female,
females, respectively, at 10 weeks and 23% and 27% reductions 26 ± 1 ng/ml; 2000 hours male, 70 ± 45 ng/ml; 2000 hours female,
in males and females, respectively, at 30 weeks compared with 76 ± 51 ng/ml. Corticosterone-replaced Pomc –/– mice (n = 8)
control Pomc+/+Tg+ mice (Figure 5, A and B).
gained significantly more weight over 9 weeks than the untreatFurthermore, both sexes of Pomc–/–Tg+ mice exhibited elevated ed Pomc–/– mice (n = 11): males, 20.3 ± 0.6 g versus 8.4 ± 1.9 g
respiratory quotients (RQs) at age 30 weeks compared with the (P < 0.005, Student’s t test); females, 13.2 ± 0.9 g versus 6.1 ± 1.1 g
other genotypes (Figure 5C). Higher RQs indicate less fatty acid (P < 0.001, Student’s t test). Corticosterone replacement also resultrelative to carbohydrate oxidation and possible shifts in energy ed in significantly greater white fat pad mass (males, 8.1 ± 0.3 g
partitioning and utilization of different energy stores (38).
versus 2.3 ± 0.7 g, P = 0.002; females, 6.9 ± 0.8 g versus 4.1 ± 0.6 g,
Caloric restriction attenuated the obesity syndrome in Pomc–/–Tg+ mice. P = 0.02, Student’s t test) and plasma leptin levels (males,
To determine whether hyperphagia or decreased metabolic rate was 73 ± 11 ng/ml versus 12 ± 7 ng/ml, P < 0.01; females, 68 ± 12 ng/ml
the primary defect in Pomc–/–Tg+ mice leading to their massive obe- versus 14 ± 4 ng/ml, P = 0.01, Student’s t test) at 17–20 weeks of
sity, we performed a pair-feeding experiment from the earliest pos- age compared with no treatment.
The Journal of Clinical Investigation
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Figure 6
Growth curves, fat mass, and plasma leptin levels of individually housed Pomc+/+Tg+, Pomc–/–,
and Pomc–/–Tg+ mice from ages 5 to 15 weeks.
(A) The effect on body weight of pair-feeding
(PF) of Pomc–/–Tg+ mice to the daily food intake
of Pomc+/+Tg+ mice starting at age 5 weeks
(n = 5–11). Repeated-measures ANOVAs over
the 10-week period showed a main effect of
group for males (F18,117 = 21.5, P < 0.0001) and
females (F18,144 = 24.6, P < 0.0001). One-factor
ANOVAs showed that Pomc–/–Tg+ pair-fed mice
differed from Pomc–/–Tg+ mice fed ad libitum
and Pomc+/+Tg+ mice fed ad libitum (P < 0.001);
Pomc–/– mice fed ad libitum also differed from
Pomc+/+Tg+ mice fed ad libitum and Pomc–/–Tg+
mice fed ad libitum (P < 0.001) but not from
Pomc–/–Tg+ pair-fed mice. (B) The effects of
pair-feeding of Pomc–/–Tg+ mice on accumulation of fat mass. The combined weight of 4 white
fat pads (renal, visceral, gonadal, and inguinal)
was different among groups in 15- to 20-weekold male (F3,17 = 50.3, P < 0.0001) and female
(F3,23 = 35.9, P < 0.0001) mice. *P < 0.05, **P < 0.001,
and ***P < 0.0001 compared with Pomc+/+Tg+;
#P < 0.0001 compared with Pomc–/–Tg+. (C and
D) The effect of pair-feeding of Pomc–/–Tg+ mice
on plasma leptin levels. Data are the means
and scattergrams of all individual leptin levels
(n = 9–19) obtained after a 16-hour overnight
fast in 9-week-old (C) and ad libitum–fed 15- to
20-week-old (D) mice of both sexes.

Using a within-subjects design, a second group of 6- to 9-weekold Pomc–/– mice was treated sequentially with corticosterone
for 16 days, ordinary drinking water for 9 days, and corticosterone for a final 9 days. The velocity of weight gain during each
corticosterone replacement period was approximately 4 g/wk,
while all mice lost weight at a rate of approximately 2 g/wk when
switched from corticosterone to water (Figure 7A, top). Separate
groups of age-matched WT C57BL/6J Pomc+/+ mice were treated
with either corticosterone or ordinary drinking water continuously for the entire 5-week study and had indistinguishable
growth curves with a velocity of weight gain of approximately
0.4 g/wk, regardless of treatment or sex (Figure 7A, bottom).
Corticosterone treatment significantly increased daily food
intake by more than 50% in all the Pomc–/– mice but had no effect
in Pomc+/+ mice of either sex (Figure 7B).
Corticosterone supplementation in the drinking water resulted in different plasma hormone levels between male and female
mice for both genotypes (Figure 7C), despite the absence of sex
differences in weight gain and food intake for either genotype.
Untreated Pomc+/+ mice exhibited a normal circadian variation
in plasma corticosterone with lower levels at 0800 hours and
higher levels at 2400 hours and sexual dimorphism with higher
levels at both time points in females. Corticosterone supplementation had little effect on this pattern in Pomc+/+ females
and failed to increase plasma levels above the sensitivity of the
RIA (12.5 ng/ml) in the 2 Pomc –/– female mice at either time
point. While most untreated Pomc+/+ males also had undetect500
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able plasma corticosterone levels at 0800 hours, corticosterone
replacement significantly increased plasma levels of the steroid
hormone at both time points in Pomc+/+ and Pomc–/– male mice,
and to a similar magnitude.
Discussion
We generated and analyzed a novel strain of compound mutant
mice with a de facto neuron-specific deficiency of POMC. The
principal finding was that the syndrome of obesity associated
with hyperphagia and metabolic disturbances characterized
originally by Yaswen et al. (7) and independently by Challis et
al. (39) was markedly accentuated in mice with the selective restoration of peripheral POMC compared with mice with a global
absence of POMC peptides.
The phenotype of Pomc–/–Tg+ mice was characterized by marked
increases in white adipose tissue with a disproportionately greater increase in subcutaneous fat, massive hepatomegaly with steatosis, and extreme insulin resistance and hyperleptinemia. In
contrast, Pomc–/– mice attained a final body mass intermediate to
WT and Pomc–/–Tg+ mice and accumulated excess fat principally
in their gonadal depots, a subset of intra-abdominal fat whose
mass is typically directly proportional to insulin resistance in
humans and mice (40, 41) whereas subcutaneous fat deposition
correlates better with increased circulating leptin (2, 41). Pomc+/–
mice also exhibited a mild obesity syndrome, similar to the intermediate phenotype observed by Coll et al. (42) in their 129 strain
Pomc+/– mice fed a high-fat diet. The predominantly C57BL/6J
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Hyperphagia and decreased energy expenditure contribute to the obesity phenotype of
Pomc mutant mice. The initial characterization of 2 independent lines of Pomc–/–
mutant mice by Yaswen et al. (7) and
later by Challis et al. (39) suggested that
both hyperphagia and decreased metabolic rate contributed to the obesity phenotype. We therefore used pair-feeding
experiments to test whether hyperphagia
and/or metabolic defects were primarily responsible for the increased body
weight in Pomc–/–Tg+ mice. If a metabolic
defect exists independently of hyperphagia, the mice would be predicted to still
develop obesity when food-restricted.
Pomc–/–Tg+ mutant mice slightly reduced
their body weight during the first week
of pair-feeding. However, after prolonged caloric restriction, the absolute
body weight of Pomc–/–Tg+ mice rebounded, and their growth velocity remained
roughly parallel to that of freely feeding
Pomc+/+Tg+ mice. Furthermore, leptin
levels remained elevated and the pair-fed
mice
continued to accumulate fat mass,
Figure 7
The effect on body weight, food intake, and plasma corticosterone levels of corticosterone (Cort) supporting a combination of disturreplacement (25 µg/ml drinking water) in Pomc–/– and C57BL/6J Pomc+/+ mice starting at age 6–9 bances in metabolism and appetite. An
weeks. Pomc+/+ mice (n = 20; 10 males and 10 females) were separated into 2 groups and received unavoidable caveat for the pair-feeding
either water (n = 10) or corticosterone (n = 10) for 34 consecutive days. All Pomc–/– mice (n = 5; experiment is that body weight of the
3 males and 2 females) were first given corticosterone (days 1–16, filled circles), then water (days Pomc–/–Tg+ mice was already significant16–25, open circles), and finally corticosterone again (days 25–34, filled circles). (A) Weight gain
ly greater than that of control Pomc+/+Tg+
was significantly accelerated by corticosterone replacement in Pomc–/– mice but was unaltered
mice
at the start. Attempts to individuin Pomc+/+ mice of either sex. (B) Average daily food intake measured over a 7-day period was
ally
house
mice immediately after wean–/–
increased in Pomc mice (corticosterone versus water, **P = 0.01, paired t test) but was unchanged
by corticosterone treatment in Pomc+/+ mice. (C) Plasma corticosterone levels obtained under ing when the weight differences were
stress-free conditions at 0800 and 2400 hours. Corticosterone was always less than 12.5 ng/ml minimal led to a failure to thrive in many
(assay sensitivity) for Pomc–/– mice without replacement (data not shown).
instances, resulting in a compromise of
age 4–5 weeks for initiation of pair-feeding with individually housed mice.
In our study, hyperphagia was evident early in both Pomc–/–Tg+
genetic background of mice in our studies likely accounts for
the increased obesity susceptibility of Pomc+/– animals on low-fat and Pomc–/– mice whether food intake was expressed in absolute
chow. Comparisons of young and middle-aged animals showed values or normalized to total estimated metabolic mass (37).
that excess storage of white fat occurred earlier in Pomc–/–Tg+ than However, in the following weeks, absolute food consumption was
in Pomc–/– mice. In parallel, plasma leptin levels were already 10- not modified, despite a sustained increase in body weight. Consefold elevated in 6-week-old Pomc–/–Tg+ mice compared with WT quently the rank order for feed efficiency (ratio of weight gain to
controls, while Pomc–/– mice had essentially normal leptin levels, caloric intake) between ages 6 and 9 weeks among genotypes was
reflecting their delayed accumulation of excess fat.
Pomc–/–Tg+ > Pomc–/– > Pomc+/+Tg+, indicating a predominant partiMales and females of each mutant genotype generally exhib- tioning of fuel stores into fat in Pomc–/–Tg+ mice and Pomc–/– mice.
ited parallel changes in the measured biochemical, physiologi- This trend of increased feed efficiency was even more pronounced
cal, and behavioral parameters that assessed energy balance. The in older animals, especially in adult 26-week-old Pomc–/– mice,
magnitude of change for many variables, however, was often whose absolute daily food intake was indistinguishable from
influenced by sex. Notably, the greatest percentage increase in that of age- and sex-matched Pomc+/+ mice. After correction for
total body mass and subcutaneous fat relative to WT controls metabolic mass, both Pomc–/– and Pomc–/–Tg+ mice appeared to be
occurred in female Pomc –/–Tg + mice, even though they exhib- hypophagic compared with their WT siblings at 26 weeks. If we
ited only minimal dysregulation of their HPA axis relative to assume that caloric intake must be increased proportionately to
Pomc–/–Tg+ males. Conversely, the phenotypic effects of Pomc+/– body mass to maintain body weight gain, hyperphagia cannot fully
mutations were largely evident only in males. These sexual explain the maintenance of obesity in adult animals.
Our data differ from those obtained in a pair-feeding study of
dimorphisms in the mutant mice are most likely a result of sex
steroid interactions on multiple pathways known to affect ener- MC4-R KO mice (20), where a metabolic defect was suggested to
be the primary mechanism for obesity, accompanied by secondgy homeostasis (43–45).
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ary hyperphagia to support the animals’ increased body weight.
However, another set of experiments comparing younger (3- to
5-week-old) and adult MC4-R KO mice indicated that the earliest onset of excessive fat accumulation was a result of primary
hyperphagia partially counteracted by increased metabolic rate
(46). The physiological mechanisms supporting obesity in either
Pomc–/– or Pomc–/–Tg+ mice would not necessarily be expected to be
identical to those in MC4-R KO mice, because of the additional
role of MC3-R in maintaining energy homeostasis. MC3-R KO
mice have a unique phenotype characterized by increased fat mass
and decreased lean body mass, hypophagia with increased feed
efficiency, and unusual metabolic changes (23, 24). Indeed, the
growth and obesity phenotype of the Pomc–/–Tg+ mice is apparently most similar to that of the combined MC4-R and MC3-R
double-KO mice, which exhibit an additive phenotype for absolute increase in body mass compared with either of the singlereceptor-KO mice (24). Conclusions from each of these previous
studies, as well as from our own experiments, on the primacy of
hyperphagia versus decreased metabolism must be tempered by
the recognized difficulties inherent in the quantitation of energy
expenditure and comparison between animals that differ greatly
in body mass and composition.
Peripheral and central actions of glucocorticoids combine to augment the obesity phenotype in Pomc–/–Tg+ versus Pomc–/– mice. Glucocorticoids might
function peripherally to produce the observed genotype differences
in the onset of fat accumulation and elevation of plasma leptin, not
only by favoring leptin production (47, 48), but also by inducing a
repartition of lipid storage among specific fat pads including subcutaneous fat and the liver, where gluconeogenesis is stimulated by
corticosterone. Intra-abdominal fat is known to exhibit an increased
lipolytic response via the stimulation of adrenergic receptors (49).
Because Pomc–/– mice lack secretion of epinephrine in addition to
corticosterone from their atrophic adrenals (7), reduced lipolysis in
gonadal fat could lead to increased storage in this site relative to subcutaneous adipocytes and explain partitioning differences.
Adipose tissue produces leptin in conditions of positive energy balance (50), thereby contributing to reduced caloric intake,
increased metabolism, and a net restoration of energy homeostasis. However, Pomc–/–Tg+ mice displayed hyperphagia and decreased
metabolic rate despite elevated leptin levels. Although leptin
directly stimulates POMC neurons (6), recent data have demonstrated that the effects of exogenous leptin administration on food
intake and body weight were intact in 4-week-old nonobese Pomc–/–
mice and attenuated in 12- to 15-week-old obese Pomc–/– mice,
suggesting that leptin resistance develops concordantly with the
increasing weight by a POMC-independent pathway (39). Glucocorticoids likely contribute to the apparently greater leptin resistance in Pomc–/–Tg+ mice and explain their reduced metabolism
and increased body weight compared with Pomc–/– mice. Indeed,
glucocorticoids play an inhibitory role in leptin actions. Leptin has
more potent and long-lasting effects to decrease body weight and
food intake when administered to adrenalectomized rats (51, 52).
Furthermore, glucocorticoids can attenuate the effects of centrally
administered leptin on feeding and metabolism (51).
Glucocorticoids also exhibit a permissive role in the development
of obesity that is independent of leptin, but associated with hyperinsulinemia and insulin resistance. In genetic models of obesity,
such as ob/ob mice and fa/fa rats, withdrawal of glucocorticoids by
adrenalectomy either prevents or ameliorates several defects associated with obesity (increased food intake, increased body weight,
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increased fat storage, high plasma glucose and insulin levels), and
these effects can be reversed by glucocorticoid replacement (28, 32,
53, 54). Some of these responses may be attributed to a sensitizing effect of glucocorticoid withdrawal on the anorectic action of
MC4-R activation (52). However, similar reductions of circulating
corticosterone by adrenalectomy do not attenuate diet-induced
obesity in WT C57BL/6 mice (55).
Additional studies have suggested that the observed anabolic
effects of glucocorticoids are mediated in part at the level of the
CNS. Smaller doses of glucocorticoids are more efficient at inducing obesity after injection directly into the brain than after injection
into the periphery (56–58), and this difference is presumably mediated by central glucocorticoid receptors. In support of this central
role, selective inactivation of glucocorticoid receptors in the CNS
affects energy accumulation by reducing food intake and growth of
lean body mass, but increasing fat accumulation (59).
Our data as well as the literature support the hypothesis that the
severe metabolic syndrome of Pomc–/–Tg+ mice results from permissive actions of glucocorticoids in combination with a central loss of
POMC signaling rather than the simpler alternative of direct effects
of hypercorticosteronemia. Indeed, although male Pomc–/–Tg+ mice
exhibited clearly elevated corticosterone levels, the greater percentage increase in body weight in Pomc–/–Tg+ than in Pomc–/– mice
occurred in females. Interestingly, the adipose tissue with the disproportionately greatest increase in mass in the Pomc–/–Tg+ mice
was subcutaneous inguinal fat and not visceral fat as might be predicted from hypercorticosteronemia. Mice with central overexpression of corticotropin-releasing hormone and a similar pattern of
chronic hypercorticosteronemia to that of Pomc–/–Tg+ mice do not
gain excessive total weight and in fact have reduced body weight,
although with anecdotally reported truncal obesity (60). We have
also found that male somatostatin-deficient mice exhibit a very
similar pattern of enlarged adrenal glands and elevated peak diurnal corticosterone levels comparable to that in male Pomc–/–Tg+ mice
but do not develop the obesity syndrome (ref. 61 and our unpublished data). Finally, many other genetic models of obesity in rats
and mice (fa/fa, ob/ob, db/db, and Ay/a) exhibit elevated circulating
corticosterone levels or increased tissue corticosterone, although
excessive glucocorticoid tone is not considered to be the primary
mechanism for obesity (62).
Therefore, to further analyze the contribution of glucocorticoids with a concomitant absence of central and peripheral
POMC to energy balance, we treated Pomc–/– mice with corticosterone in their drinking water. Acute treatment induced an
immediate increase in the rate of body weight gain and food
consumption in Pomc–/– mice. These effects were rapidly reversed
with treatment interruption and restored after the animals were
again treated with corticosterone. Continuous replacement for
several weeks was accompanied by accumulation of fat mass
and hyperleptinemia, nearly comparable to the genetic rescue
of pituitary POMC production, in both male and female Pomc–/–
mice. In contrast, the identical corticosterone supplementation
of drinking water did not alter weight gain or food intake in
WT male or female C57BL/6J mice, consistent with previously
published results (63). These data clearly suggest a permissive
or synergistic action of glucocorticoids in Pomc–/– mice. A recent
study using an identical method of corticosterone replacement
in a different strain of Pomc–/– mice on a 129 genetic background
reported similar metabolic consequences but with greater
adverse effects on the animals’ overall health (64).
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In a dynamic homeostatic system, the interaction of glucocorticoids with numerous factors to exert its overall effects on
energy balance is complicated by the impossibility of keeping
only 1 important physiological factor constant without changing others. The effects of corticosterone have to be considered
together with the absence or presence of POMC peptides, either
globally or specifically from the brain. Thus, a contribution of
peripheral melanocortin peptides to the obesity phenotype independently of glucocorticoid secretion cannot totally be excluded
from our study, since the phenotype of Pomc–/–Tg+ mice in the
absence of circulating corticosterone has not been evaluated.
Peripheral administration of αMSH agonists has been shown to
cause weight loss in mice with high-fat diet–induced obesity and
genetically obese mice (65–67), and in fa/fa rats (68, 69). In addition, systemic injection of [Nle4, D-Phe7]-melanocyte-stimulating
hormone reduced food intake and weight gain in Pomc–/– mice
(7). Although potent and degradation-resistant MSH analogs
have been suggested to exert much of their effect within the CNS
after peripheral administration (12), other studies indicate that
systemically administered MTII crossed the blood-brain barrier
poorly (70) and may also act on peripheral systems.
In conclusion, the present study confirms and extends previous reports that Pomc –/– mice develop obesity with modest
hyperphagia and decreased metabolic rate despite the absence
of circulating glucocorticoids (7, 39). This phenotype was not
averted by restoration of physiological levels of pituitary POMC
peptides including αMSH but instead was exacerbated by a combination of severe hyperphagia and increased feed efficiency.
Corticosterone treatment of Pomc–/– mice recapitulated the phenotype, indicating that a permissive action of glucocorticoids
together with the CNS deficiency of POMC accounts for the
morbid obesity in genetically altered Pomc–/–Tg+ mice. A potential contribution of peripheral POMC peptides to the phenotype
may have been masked by the metabolic effect of glucocorticoids
and could be further explored in future experiments by clamping of corticosterone in rescued mice or creation of a de facto
lack of peripheral POMC. Finally, the sustained hyperphagia,
velocity of weight gain, and eventual peaks of total body and fat
mass achieved in Pomc–/–Tg+ mice despite a diet containing only
5% fat-derived calories are all significantly greater than those
reported previously for any of the single-gene MC4-R, MC3-R, or
β-endorphin KO mouse strains (19, 23–25). Indeed, the extreme
obesity phenotype of Pomc –/–Tg + mice strongly supports the
contention made previously by Chen et al. (24), based on their
genetic cross of MC4-R and MC3-R KOs to produce a doubleKO strain, that the 2 melanocortin receptor subtypes play critical and distinct roles in the CNS regulation of energy balance by
POMC-derived peptides.
Methods
Transgene construction. A 9.7-kb EcoRI-EcoRI mouse genomic DNA fragment
containing the 3 Pomc exons and proximal promoter elements (35) was
subcloned into pBluescript SK (Stratagene) and used to construct the pituitary-specific POMC rescue transgene pHalEx2*. A pair of complementary
23-bp oligonucleotides (5′-CCCGGGCTCGAGTTTAAAGCGCG-3′ and
5′-CGCGCTTTAAACTCGAGCCCGGG-3′) was annealed to form a bluntended double-stranded DNA fragment and ligated into a StuI site in the
5′ untranslated region of exon 2. The correctly inserted oligonucleotide
was designed for specific detection of pHalEx2* mRNA without altering
translation or processing of POMC.
The Journal of Clinical Investigation

Generation and breeding of mice. A colony of Pomc mutant mice on a
B6;129X1;129S6 hybrid genetic background was established as described
previously (71). The novel strain of transgenic mice was generated by
nuclear microinjection of linearized pHalEx2* Tg DNA into B6D2 F2
hybrid 1-cell embryos using standard techniques. The pHalEx2* Tg allele
was backcrossed from a single identified founder to inbred C57BL/6J
mice (Jackson Laboratory) for 2 consecutive generations and subsequently
crossed onto the Pomc–/– genetic background by an additional 2 generations of double-heterozygous matings. Consequently, the resulting hybrid
genetic background of the compound mutant and sibling control mice
was approximately 80% C57BL/6, 10% DBA/2, and 10% 129X1;129S6. Mice
were maintained under controlled temperature and photoperiod (12 hours
light, 12 hours dark; lights on at 0700 hours) with free access to water and
a standard rodent chow (5% fat, 19% protein, 5% fiber, 3.4 kcal/g), except
where noted. All experimental protocols were approved by the Oregon
Health & University Institutional Animal Care and Use Committee and
followed Public Health Service guidelines.
Genotyping. Three separate PCR reactions were used to identify the Pomc
alleles from genomic DNA samples. Touchdown PCR conditions were:
15 cycles at 94°C for 30 seconds, 64°C minus 1°C per cycle for 30 seconds, and 72°C for 30 seconds; 15 cycles of 94°C for 30 seconds, 50°C
for 30 seconds, and 72°C for 30 seconds; and 72°C for 3 minutes. The
primer pairs and sizes of specific amplified bands were: Pomc+ 318-bp
product, primer pair i 5′-GCTTGCATCCGGGCTTGCAAACT-3′ and ii
5′-AGCAACGTTGGGGTACACCTTC-3′; Pomc– approximately 300-bp
product, primer pair iii 5′-TTGTTAACTTGTTTATTGCAGCTT-3′ and iv
5′-ATGAGAAATTGGGCCATGGGACTGAC-3′; and pHalEx2* Tg 226-bp
product, primer pair v 5′-TAGTGTTGGCTCAATGTCCT-3′ and vi 5′GCTCTCCAGGCACCAGCTCC-3′.
Analysis of POMC peptide expression. Mice were anesthetized
with 2% Avertin, perfused via the left ventricle with 4% buffered
paraformaldehyde, and their brains and pituitary glands were removed
and postfixed for 16 hours. Immunohistochemistry was performed on
12-µm frozen pituitary sections (after equilibration in 20% sucrose) and
free-floating 50-µm vibratome sections incubated with 2% normal goat
serum and 0.3% Triton X-100 in 10 mM potassium phosphate–buffered saline containing anti–rat ACTH (1:16,000) or anti–β-endorphin
(1:16,000) primary antiserum (both from A. Parlow, National Hormone
and Peptide Program, Harbor-UCLA Medical Center, Torrance, California, USA) at 4°C overnight. Sections were then rinsed in potassium
phosphate–buffered saline and sequentially incubated with 20 µg/ml
biotinylated goat anti-rabbit IgG (Vector Laboratories) for 2 hours
at 25°C followed by incubation with an avidin-biotin/HRP complex
(VECTASTAIN Elite ABC Kit; Vector Laboratories) for 1 hour at 25°C.
Reaction product was revealed with 1 mg/ml diaminobenzidine containing 0.03% H2O2, yielding a brown precipitate.
For quantitation of αMSH, individual whole pituitary glands and 15- to
20-mg blocks containing the medial basal hypothalamus were collected from
mice into tubes with 0.5 ml 2% acetic acid containing 10 mg/ml BSA. Peptides were extracted by 3 rounds of freeze-thawing and sonication, insoluble
material was removed by centrifugation, and supernatants were neutralized
with 10 M NaOH. Serial dilutions of the tissue extracts were prepared in
assay buffer for RIA according to the manufacturer’s instructions (EURIAα-MSH; Euro-Diagnostica, ALPCO). Stated cross-reactivities of the assay are:
αMSH, 100%; des-acetyl-αMSH, 100%; and des-amido-αMSH, ACTH 1-13,
ACTH 1-24, ACTH 1-39, βMSH, and γMSH, all less than 0.002%.
General study design. Two cohorts of mice were generated by breeding
strategies described above. The first cohort consisted of approximately
250 mice that were housed in groups of 4–6 mixed-genotype first-degree
relatives for most of their lifetimes except where indicated. These mice
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were provided food ad libitum and weighed weekly from ages 1 to 26
weeks, and then subgroups were killed at subsequent time points for
body composition and other analyses. A second younger cohort of
approximately 100 mice was generated for pair-feeding and corticosterone replacement experiments.
Pair-feeding experiments and corticosterone replacement. Pomc+/+Tg+, Pomc–/–,
and Pomc–/–Tg+ mice of both sexes from cohort 2 were individually housed
starting at age 4–5 weeks (approximately 1–2 weeks after weaning) until
conclusion of the experiments, provided with food ad libitum, and weighed
weekly. For pair-feeding experiments, food intake was measured daily, and
a subgroup of Pomc–/–Tg+ mice were provided the average amount of food
that their sex- and age-matched Pomc+/+Tg+ controls consumed daily as a
single meal at 1800 hours from age 5 weeks to the end of the experiment.
To determine the contribution of circulating glucocorticoids in development of the obesity phenotype, other subgroups of body weight–matched
Pomc–/– mice were treated with corticosterone (25 µg/ml) in their drinking
water either continuously or intermittently starting at age 6 weeks. This
dose was chosen because previous studies showed that it restored low physiological levels of the hormone in adrenalectomized male mice. At 15–20
weeks old, mice were killed and fat pads weighed. Groups of C57BL/6J
male and female mice were supplemented with the same dose of corticosterone from ages 6 to 11 weeks to determine the effects on body weight and
food intake in WT animals.
Food consumption, basal metabolic rate, and RQ. In 6- and 9-week-old mice
individually housed from age 5 weeks, food consumption was determined
over a 24-hour period. Twenty-six-week-old mice that had been grouphoused were habituated to individual housing for 9 days to restabilize feeding behavior after the initial period of stress-induced anorexia, and then
their average 24-hour food intake was calculated over 5 consecutive measurements on days 10–14. In addition to the raw data, daily food intake was
normalized to metabolic mass using the following scaling formula: [food
intake (g)]/[body weight (g)]0.75 × 100 (37). Twenty-four-hour food intake
in the corticosterone replacement studies was calculated over 7 consecutive
daily measurements for each mouse.
Basal metabolic rate was assessed in 10- and 30-week-old mice using an
indirect open-circuit calorimeter system (Oxymax; Columbus Instruments)
consisting of acrylic chambers with dimensions of 10.5 × 20.5 × 12.5 cm
that limited spontaneous locomotor activity. Mice were placed into individual chambers at 0800 hours for 6 hours without access to food or water
for 2 consecutive days to allow for habituation. On the third day, a total
of 12 measurements were recorded from each mouse at 30-minute intervals. The inlet fresh air flow rate was 0.5 l/min with a sample-flow rate of
0.4 l/min. Each chamber was sampled for 50 seconds with a resting time
of 150 seconds. Individual basal oxygen consumption (VO2) levels were
1. Isomaa, B. 2003. A major health hazard: the metabolic syndrome. Life Sci. 73:2395–2411.
2. Havel, P.J. 2001. Peripheral signals conveying metabolic information to the brain: short-term and
long-term regulation of food intake and energy
homeostasis. Exp. Biol. Med. 226:963–977.
3. Dallman, M.F., et al. 2003. A spoonful of sugar:
feedback signals of energy stores and corticosterone regulate responses to chronic stress. Physiol.
Behav. 79:3–12.
4. Low, M.J. 2004. Role of proopiomelanocortin
neurons and peptides in the regulation of energy
homeostasis. J. Endocrinol. Invest. 27:95–100.
5. Ellacott, K.L., and Cone, R.D. 2004. The central
melanocortin system and the integration of shortand long-term regulators of energy homeostasis.
Recent Prog. Horm. Res. 59:395–408.
6. Cowley, M.A., et al. 2001. Leptin activates anorexigenic POMC neurons through a neural network in
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established by averaging of the 3 lowest of 12 VO2 measurements. CO2
production from each mouse was also recorded simultaneously and used
to calculate the RQ (RQ = VCO2/VO2) at each 30-minute interval.
Plasma glucose and hormone levels. Blood for glucose, insulin, and leptin
measurements was obtained by tail bleeding and collected into heparinized capillary tubes between 0800 and 1000 hours following a 16- or
24-hour fast from mice of the indicated ages or from ad libitum–fed
15- to 20-week-old mice. Samples were centrifuged at 3,000 g for 5 minutes, and the plasma was stored frozen at –20°C. The first drop of whole
blood was used for glucose determination using a glucometer (Elite XL;
Bayer). To measure circadian corticosterone levels, blood was collected
from the tail tip of unanesthetized mice at the indicated time points. All
samples were collected less than 1 minute after cage disturbance, and
only 1 sample was collected per mouse per day. Plasma hormones were
measured using a corticosterone RIA (MP Biomedicals Inc.), a rat insulin RIA (Linco Research Inc.), and a mouse-specific leptin RIA (Linco
Research Inc.) according to the manufacturers’ instructions.
Statistics. All data presented are the mean ± SEM unless otherwise stated
and were analyzed by either multifactor ANOVA with sex and genotype
as independent variables or repeated-measures ANOVA for body weight
curves and RQ, using StatView Power PC version for Macintosh (version
5.0.1; SAS Institute Inc.). Post hoc pairwise comparisons between groups
were performed by Fisher’s protected least squares difference. Two-tailed
Student’s t test was used for comparisons involving only 2 groups. P values
less than 0.05 were considered significant.
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